<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0901244693
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Lintra
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LINAGLIPTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        79.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BH05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lintra&trade; contains the active substance linagliptin which belongs to a group of<br />medicines called &ldquo;oral anti-diabetics&rdquo;. Oral anti-diabetics are used to treat<br />high blood sugar levels. They work by helping the body to reduce the level of<br />sugar in your blood.<br />Lintra&trade; is used for &lsquo;type 2 diabetes&rsquo; in adults, if the disease cannot be<br />adequately controlled with one oral anti-diabetic medicine<br />(metformin or sulphonylureas) or diet and exercise alone. Lintra&trade; may be<br />used together with other anti-diabetic medicines e.g. metformin,<br />sulphonylureas (e.g. glimepiride, glipizide), empagliflozin, or insulin.<br />It is important to keep following the advice about diet and exercise that you<br />have been given by your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Lintra&trade;<br />&bull; if you are allergic to linagliptin or any of the other ingredients of this<br />medicine (listed in section 6).<br />Warnings and precautions<br />Talk to your doctor, pharmacist or nurse before taking Lintra&trade; if you:<br />&bull; have type 1 diabetes (your body does not produce any insulin) or diabetic<br />ketoacidosis (a complication of diabetes with high blood sugar, rapid weight<br />loss, nausea or vomiting). Lintra&trade; should not be used to treat these<br />conditions.<br />&bull; are taking an anti-diabetic medicine known as a &lsquo;sulphonylurea&rsquo;<br />(e.g. glimepiride, glipizide), your doctor may want to reduce your dose of<br />sulphonylurea when you take it together with Lintra&trade; in order to avoid your<br />blood sugar going too low.<br />&bull; have had allergic reactions to any other medicines that you take to control<br />the amount of sugar in your blood.<br />&bull; have or have had a disease of the pancreas.<br />If you have symptoms of acute pancreatitis, like persistent, severe stomach<br />ache (abdominal pain), you should consult your doctor.<br />If you encounter blistering of the skin it may be a sign for a condition called<br />bullous pemphigoid. Your doctor may ask you to stop Lintra&trade;.<br />Diabetic skin lesions are a common complication of diabetes. You are advised<br />to follow the recommendations for skin and foot care that you are given by<br />your doctor or nurse.<br />Children and adolescents<br />Lintra&trade; is not recommended for children and adolescents under 18 years.<br />Other medicines and Lintra&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken or might<br />take any other medicines.<br />In particular, you should tell your doctor if you are using medicines containing<br />any of the following active substances:<br />&bull; Carbamazepine, phenobarbital or phenytoin. These may be used to control<br />fits (seizures) or chronic pain.<br />&bull; Rifampicin. This is an antibiotic used to treat infections such as tuberculosis.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor or pharmacist for advice before<br />taking this medicine.<br />It is unknown if Lintra&trade; is harmful to the unborn child. Therefore, it is<br />preferable to avoid using Lintra&trade; if you are pregnant.<br />It is not known if Lintra&trade; passes into human breast milk. A decision must be<br />made by your doctor whether to discontinue breast-feeding or to<br />discontinue/abstain from Lintra&trade; therapy.<br />Driving and using machines<br />Lintra&trade; has no or negligible influence on the ability to drive and use<br />machines.<br />Taking Lintra&trade; in combination with medicines called sulphonylureas and/or<br />insulin can cause too low blood sugar levels (hypoglycaemia), which may<br />affect your ability to drive and use machines or work without safe foothold.<br />However, more frequent blood glucose testing might be recommended to<br />minimise the risk for hypoglycaemia, especially when Lintra&trade; is combined<br />with sulphonylurea and/or insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />The recommended dose of Lintra&trade; is one 5 mg tablet once a day.<br />You can take Lintra&trade; with or without food.<br />Your doctor may prescribe Lintra&trade; together with another oral anti-diabetic<br />medicine. Remember to take all medicines as directed by your doctor to<br />achieve the best results for your health.<br />If you take more Lintra&trade; than you should<br />If you take more Lintra&trade; than you should, talk to a doctor immediately.<br />If you forget to take Lintra&trade;<br />&bull; If you forget to take a dose of Lintra&trade;, take it as soon as you remember it.<br />However, if it is nearly time for the next dose, skip the missed dose.<br />&bull; Do not take a double dose to make up for a forgotten dose. Never take two<br />doses on the same day.<br />If you stop taking Lintra&trade;<br />Do not stop taking Lintra&trade; without first consulting your doctor. Your blood<br />sugar levels may increase when you stop taking Lintra&trade;.<br />If you have any further questions on the use of this medicine, ask your doctor,<br />pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />Some symptoms need immediate medical attention<br />You should stop taking Lintra&trade; and see your doctor immediately if you<br />experience the following symptoms of low blood sugar: trembling,<br />sweating, anxiety, blurred vision, tingling lips, paleness, mood change or<br />confusion (hypoglycaemia). Hypoglycaemia (frequency: very common,<br />may affect more than 1 in 10 people) is an identified side effect when<br />Lintra&trade; is taken together with metformin and a sulphonylurea.<br />Some patients have experienced allergic reactions (hypersensitivity;<br />frequency uncommon, may affect up to 1 in 100 people) while taking<br />Lintra&trade; alone or in combination with other medicinal products for<br />the treatment of diabetes, which may be serious, including wheezing and<br />shortness of breath (bronchial hyper-reactivity; frequency not known,<br />frequency cannot be estimated from the available data). Some patients<br />experienced rash (frequency uncommon), hives (urticaria; frequency rare,<br />may affect up to 1 in 1000 people), and swelling of the face, lips, tongue,<br />and throat that may cause difficulty in breathing or swallowing<br />(angioedema; frequency rare). If you experience any of the signs<br />of illness mentioned above, stop taking Lintra&trade; and call your doctor<br />right away. Your doctor may prescribe a medicine to treat your allergic<br />reaction and a different medicine for your diabetes.<br />Some patients have experienced inflammation of the pancreas<br />(pancreatitis; frequency rare, may affect up to 1 in 1000 people) while<br />taking Lintra&trade; alone or in combination with other medicinal products<br />for the treatment of diabetes.<br />STOP taking Lintra&trade; and contact a doctor immediately if you notice any<br />of the following serious side effects:<br />&bull; Severe and persistent pain in the abdomen (stomach area) which might<br />reach through to your back, as well as nausea and vomiting, as it could be<br />a sign of an inflamed pancreas (pancreatitis).<br />Some patients have had the following side effects while taking<br />Lintra&trade; alone or in combination with other medicinal products for the<br />treatment of diabetes:<br />&bull; Common: level of lipase in the blood increased.<br />&bull; Uncommon: inflamed nose or throat (nasopharyngitis), cough,<br />constipation (in combination with insulin), level of amylase in the blood<br />increased.<br />&bull; Rare: blistering of skin (bullous pemphigoid).<br />Reporting of side effects<br />If you get any side effects talk to your doctor, pharmacist or nurse. This<br />includes any possible side effects not listed in this leaflet. By reporting<br />side effects you can help provide more information on the safety of this<br />medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use this medicine after the expiry date which is stated on the<br />blister and the carton after &lsquo;EXP&rsquo;.<br />Do not store above 30 &deg;C<br />Do not throw away medicines via wastewater or household waste. Ask<br />your pharmacist how to throw away medicines you no longer use. These<br />measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each film-coated tablet contains 5 mg of Linagliptin<br />- The other ingredients are: Mannitol, Pregelatinised starch ,<br />Maize starch, Copovidone, Magnesium stearate, Hydroxy propyl methyl<br />Cellulose, Polyethylene Glycol, Talc, Titanium Dioxide and Iron oxide<br />red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                tablets debossed with "JP" on one side and “BH” on the other side.
• Lintra™ 5 mg tablets are available in a box of 3 blisters, 10 tablets per
each blister.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Factory Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111. Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last reviewed at 12/2020; Version number 01.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="ltr">على المادة الفعالة لیناجلیبتین التي تنتمي إلى مجموعة من الأدویة تسمى &trade; یحتوي عقار لینترا<br />&quot;مضادات السكري عن طریق الفم&quot;. یتم استخدام مضادات السكري عن طریق الفم لعلاج ارتفاع<br />مستویات السكر في الدم. وھي تعمل عن طریق مساعدة الجسم على تقلیل مستوى السكر في الدم.<br />ل &quot;داء السكري من النوع ۲&quot; لدى البالغین ، إذا كان لا یمكن السیطرة على &trade; یستخدم لینترا<br />المرض بشكل كاف باستخدام دواء فموي واحد مضاد للسكري (المیتفورمین أو السلفونیل یوریا)<br />جنبًا إلى جنب مع &trade; أو النظام الغذائي وممارسة الریاضة بمفردھم. یمكن استخدام عقار لینترا<br />الأدویة الأخرى المضادة للسكري مثل المیتفورمین أو السلفونیل یوریا (مثل جلیمیبیرید أو<br />جلیبیزید) أو إمباجلیفلوزین أو الأنسولین.<br />من المھم الاستمرار في اتباع النصائح حول النظام الغذائي وممارسة الریاضة التي قدمھا لك<br />طبیبك أو الممرضة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&trade; یُحظر علیك تناول عقار لینترا<br />&bull; إذا كنت تعاني من حساسیة تجاه مادة لیناجلیبتین أو تجاه أي مكون من المكونات الأخرى الداخلة<br />.( في تركیب ھذا الدَّواء (المدرجة في القسم رقم ٦<br />تحذیرات واحتیاطات:<br />في &trade; استشر طبیبك المعالج أو الصیدلي أو الممرض(ة) المتابع(ة) لحالتك قبل تناوُل عقار لینترا<br />الحالات التالیة:<br />&bull; إذا كُنت تعاني من مرض السكري من النوع الأول (حیث لا یفرز الجسم الأنسولین) أو الحماض<br />الكیتوني السكري (من مضاعفات مرض السكري مع ارتفاع نسبة السكر في الدم ، وفقدان الوزن<br />لعلاج ھذه الحالة. &trade; السریع ، و غثیان أو قيء). یحظر علیك تناول لینترا<br />&bull; إذا كُنت تستخدم دواء أخر لعلاج مرض السكري معروف باسم&quot;سلفونیلیوریا&quot; (مثل جلیمبیرید ،<br />جلیبیزید) ، حیث قد یرغب طبیبك المعالج في تقلیل جرعة سلفونیلیوریا عند استخدامھم بمصاحبة<br />لتجنب انخفاض السكر في الدم (نقص سكر الدم). &trade; عقار لینترا<br />&bull; كان لدیك حساسیة تجاه أي أدویة أخرى تتناولھا للتحكم في كمیة السكر في دمك.<br />&bull; إذا كُنت تُعاني أو قد عانیت مسبقًا من مرض بالبنكریاس. یتعین علیك استشارة طبیبك المعالج،<br />إذا كُنت تعاني من أعراض التھاب البنكریاس الحاد، مثل ألم مستمر وشدید في المعدة (البطن).<br />&bull; إذا عانیت من ظھور بثور في الجلد فقد تكون أحد أعراض حالة تسمى شَبیھُ الفُقَاع. قد یَطلب<br />.&trade; منك طبیبك المعالج إیقاف تناول عقار لینترا<br />تُعد اضطرابات الجلد الناتجة عن الإصابة بمرض السكري أحد مضاعفات مرض السكري<br />الشائعة. یتعین علیك اتباع نصائح العنایة بالبشرة والقدم المقدمة من قبل طبیبك المعالج أو<br />الممرض(ة) المتابع(ة) لحالتك.<br />الأطفال و المراھقین<br />في المرضى من الأطفال والمراھقین الذین تقل أعمارھم عن ۱۸ &trade; لا یُوصى باستخدام عقار لینترا<br />عامًا.<br />مع الأدویة الأخرى &trade; تناوُل عقار لینترا<br />یُرجى إبلاغ الطبیب المُعالج لك، إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أیَّة أدویة أخرى.<br />یُعد أمرًا ھامًا للغایة أن تخبر طبیبك المعالج إذا كنت تتناول أي من الأدویة التالیة:<br />&bull; كَرْبامازِیبین أو فینوباربیتال أو فینیتوین، وھي أدویة تُستخدم لعلاج نوبات الصرع أو الآلام<br />المزمنة.<br />&bull; ریفامبیسین، وھو عبارة عن مضاد حیوي یُستخدم لعلاج حالات العدوى، مثل مرض السُّل.<br />الحمل والرضاعة الطبیعیة<br />إذا كنتِ حاملًا أو تمارسین الرضاعة الطبیعیة أو تعتقدین أنكِ حاملاً أو تخطِّطین لذلك، فاستشیري<br />طبیبك المعالج أو الصیدلي للحصول على النصیحة قبل تناوُل ھذا الدَّواء.<br />إذا كنتِ حاملًا. فمن غیر المعروف ما إذا كان الدواء یُلحق أي &trade; یحظر علیكِ تناول عقار لینترا<br />أضرار بالجنین أم لا.<br />من غیر المعروف ما إذا كان لیناجلیبتین یفرز في لبن الأم أم لا. استشیري طبیبك المعالج إذا كنتِ<br />ترغبین بالرضاعة الطبیعیة أثناء تناوُل ھذا الدَّواء.<br />القیادة واستخدام الآلات<br />أي تأثیر یُذكر في القدرة على قیادة السیارات واستخدام الآلات. &trade; لا یشكل عقار لینترا<br />بمصاحبة مجموعة من الأدویة تسمى سلفونیل &trade; وبالرغم من ذلك، قد یؤدي تناوُل عقار لینترا<br />یوریا أو مع الأنسولین إلى تقلیل نسبة السكر في الدم، مما یُؤثر على قدرتك على قیادة السیارات<br />واستخدام الآلات أو العمل بتركیز ووعي كامل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا ھذا الدَّواء تمامًا كما أخبرك طبیبك المعالج. یُرجى استشارة طبیبك أو الصیدلي إذا لم<br />تكن متأكدًا من كیفیة التَّناوُل.<br />ھي قرص واحد ٥ ملجم مرة واحدة في الیوم. &trade; الجرعة الموصى بھا من عقار لینترا<br />مع أو بدون طعام. &trade; یمكنك تناول عقار لینترا<br />مع دواء آخر مضاد للسكري عن طریق الفم. تذكر أن تأخذ جمیع &trade; قد یصف طبیبك عقار لینترا<br />الأدویة حسب توجیھات الطبیب لتحقیق أفضل النتائج لصحتك.<br />&trade; إذا تناولت كمیة أكثر مما یجب من عقار لینترا<br />أقراص، علیك التحدث الى الطبیب فورا. &trade; إذا تناولت كمیة أكثر مما یجب من عقار لینترا<br />&trade; إذا نسیت تناوُل عقار لینترا<br />فتناوُلھا بمُجرد تذكُّرك لھا. ومع ذلك إذا كان قد ،&trade; &bull; إذا نسیت تناوُل إحدى جُرعات عقار لینترا<br />حان موعد الجرعة التالیة، فتجاوز الجرعة التي نسیتھا.<br />&bull; لا تتناول جرعة مضاعفة لتعویض جرعة نسیتھا. یحظر تناول جرعتین في آنً واحد .<br />&trade; إذا توقفت عن تناول عقار لینترا<br />دون استشارة طبیبك أولاً. قد تزید مستویات السكر في الدم عند &trade; لا تتوقف عن تناول عقار لینترا<br />&trade; التوقف عن تناول عقار لینترا<br />إذا كانت لدیك أیّة أسئلة إضافیة أخرى حول تناول ھذا الدواء، فاستشر طبیبك المعالج أو الصیدلي<br />أو الممرض(ة) المتابع(ة) لحالتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد یُسبب ھذا الدواء، مثلھ مثل كافة الأدویة، آثارًا جانبیة على الرغم من عدم حدوثھا لجمیع<br />المرضى.<br />تحتاج بعض الآثار الجانبیة إلى رعایة طبیة عاجلة:<br />واستشر طبیبك المعالج فورًا إذا تعرضت للإصابة بأيً من الآثار &trade; توقف عن تناول عقار لینترا<br />الجانبیة التالیة الناتجة عن انخفاض السكر في الدم (نقص سكر الدم): رعشة أو فرط إفراز العرق<br />أو قلق أو عدم وضوح الرؤیة أو شعور بوخز في الشفاه أو شحوب اللون أو تغییرات بالمزاج أو<br />ارتباك. یُعد نقص سكر الدم (أثر جانبي شائع جدًا، قد یؤثر على أكثر من مریض واحد من بین كل<br />بمصاحبة میتفورمین أو &trade; ۱۰ مرضى) وھو أحد الآثار الجانبیة المعروفة عند استخدام عقار لینترا<br />سلفونیلیوریا.</p><p>عانى بعض المرضى من تفاعلات الحساسیة (فرط التحسس ؛ آثار جانبیة غیر شائعة، قد تؤثر<br />بمفرده أو بالاشتراك &trade; على ما یصل إلى شخص واحد من بین كل ۱۰۰ شخص) أثناء تناول لینترا<br />مع منتجات طبیة أخرى لعلاج مرض السكري ، و التي قد تكون خطیرة ، بما في ذلك أزیز<br />بالصدر وضیق التنفس (فرط الاستجابة القصبیة ؛ تكرارھا غیر معروف ، لا یمكن تقدیر التكرار<br />من البیانات المتاحة).<br />عانى بعض المرضى من طفح جلدي (ھو أثر جانبي غیر شائع)، شرى (ارتیكاریا، أثر جانبي<br />نادر)، وتورم بالوجھ والشفاه واللسان والحلق مما قد یؤدي إلى صعوبة بالتنفس أو بالبلع<br />إذا عانیت من أي من الآثار ،&trade; (وذمة وعائیة، أثر جانبي نادر). توقف عن تناول عقار لینترا<br />الجانبیة المذكورة أعلاه وأخبر طبیبك المعالج فورًا. قد یصف طبیبك المعالج دواءً<br />لعلاج تفاعلات الحساسیة ودواء آخر لعلاج مرض السُّكَّرِيّ.<br />ا من الآثار الجانبیة 􀌒 وأبلغ طبیبك المعالج فورًا، إذا لاحظت أی &trade; توقف عن تناوُل عقار لینترا<br />الخطیرة التَّالیة:<br />&bull; ألم شدید ومستمر في البطن (منطقة المعدة) قد یمتد إلى الظھر، بالإضافة إلى غثیان وقيء حیث<br />قد تكون تلك الآثار أحد أعراض التھاب بالبنكریاس (التھاب البنكریاس).<br />بمفرده أو بالاشتراك مع &trade; عانى بعض المرضى من الآثار الجانبیة التالیة أثناء تناول عقار لینترا<br />منتجات طبیة أخرى لعلاج مرض السكري:<br />&bull; آثار جانبیة شائعة: زیادة مستوى اللیباز في الدم.<br />&bull; آثار جانبیة غیر شائعة: التھاب الأنف أو الحلق (التھاب البلعوم الأنفي) ، سعال ، إمساك (عند<br />التناول بمصاحبة الأنسولین) ، وزیادة مستوى الأمیلیز في الدم.<br />&bull; آثار جانبیة نادرة: تقرحات في الجلد (الفقاع الفقاعي).<br />الإبلاغ عن الآثار الجانبیة:<br />إذا أصبت بأیة آثار جانبیة، فاستشر طبیبك المعالج أو الصیدلي أو الممرض(ة) المتابع/(ة) لحالتك.<br />ویشمل ذلك أیة آثار جانبیة مُحتمَلة غیر مُدرجة في ھذه النَّشرة. بإبلاغك عن الآثار الجانبیة،<br />یمكنك المساھمة في توفیر المزید من المعلومات حول أمان استخدام ھذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یُحفظ بعیدًا عن متناول و مرأى الأطفال.<br />لا تتناول ھذا الدَّواء بعد انتھاء تاریخ الصلاحیة المدوّن على العبوة الكرتونیة والشریط بعد كلمة<br />.&quot;EXP&quot;<br />یُحفظ في درجة حرارة لا تزید عن ۳۰ درجة مئویة.<br />لا تقمْ بالتخلّص من الأدویة عن طریق إلقائھا في میاه الصرف أو مع المخلّفات المنزلیة. استشر<br />الصیدلي الخاص بك حول كیفیة التَّخلص من الأدویة التي لم تعد تحتاج إلیھا. حیث تُساعد ھذه<br />التدابیر في الحفاظ على البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&trade; ماھي محتویات عقار لینترا<br />- المادة الفعالة ھي لیناجلیبتین<br />یحتوي كل قرص مغلف على ٥ ملجم من لیناجلیبتین<br />- المكونات الأخرى ھي:<br />مانیتول ، نشا مخلوط ، نشا الذرة ، كوبوفیدون ، ستیرات الماغنسیوم. ، ھیدروكسي بروبیل میثیل<br />السلیلوز ، بولي إیثیلین جلایكول، تلك، ثاني أكسید التیتانیوم و أكسید الحدید الأحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>على أحد &quot;JP&quot; ٥ ملجم: أقراص مغلفة لونھا أحمر فاتح ، مستدیرة الشكل، محفور علامة &trade; لینترا<br />على الجانب الآخر. &quot;BH&quot; جانبیھا و<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدویة،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- ھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />- المركز الوطني للتیقظ و السلامة الدوائیة<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفیذیة للتیقظ وإدارة الأزمات. o<br />+۹٦٦-۱۱- ھاتف: ۲۰۳۸۲۲۲ o<br />۲۳٤۰-۲۳٥٦- تحویلة: ۲۳۱۷<br />الخط الساخن للإبلاغ: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            . ۲۰۲۰ . رقم النسخة ۰۱ / تم مراجعة ھذه النشرة في ۱۲
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lintra™ 5 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 5 mg of linagliptin.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Light red coloured, round shaped, Film-coated Tablets, debossed with “JP” on one side and ‘BH’ on other
side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>linagliptin is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to<br />improve glycaemic control as:<br />monotherapy<br />&bull; when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.<br />combination therapy<br />&bull; in combination with other medicinal products for the treatment of diabetes, including insulin, when<br />these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on<br />different combinations).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The dose of linagliptin is 5 mg once daily. When linagliptin is added to metformin, the dose of metformin<br />should be maintained, and linagliptin administered concomitantly.<br />When linagliptin is used in combination with a sulphonylurea or with insulin, a lower dose of the<br />sulphonylurea or insulin, may be considered to reduce the risk of hypoglycaemia (see section 4.4)<br />Special populations<br />Renal impairment</p><p>For patients with renal impairment, no dose adjustment for linagliptin is required.<br />Hepatic impairment<br />Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment<br />but clinical experience in such patients is lacking.<br />Elderly<br />No dose adjustment is necessary based on age.<br />Paediatric population<br />The safety and efficacy of linagliptin in children and adolescents has not yet been established. No data<br />are available.<br />Method of administration<br />The tablets can be taken with or without a meal at any time of the day. If a dose is missed, it should be<br />taken as soon as the patient remembers. A double dose should not be taken on the same day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic<br />ketoacidosis.<br />Hypoglycaemia<br />Linagliptin alone showed a comparable incidence of hypoglycaemia to placebo.<br />In clinical trials of linagliptin as part of combination therapy with medicinal products not known to cause<br />hypoglycaemia (metformin), rates of hypoglycaemia reported with linagliptin were similar to rates in<br />patients taking placebo.<br />When linagliptin was added to a sulphonylurea (on a background of metformin), the incidence of<br />hypoglycaemia was increased over that of placebo (see section 4.8).<br />Sulphonylureas and insulin are known to cause hypoglycaemia. Therefore, caution is advised when<br />linagliptin is used in combination with a sulphonylurea and/or insulin. A dose reduction of the<br />sulphonylurea or insulin may be considered (see section 4.2).<br />Acute pancreatitis<br />Use of DPP-4 inhibitors has been associated with a risk of developing acute pancreatitis. Acute<br />pancreatitis has been observed in patients taking linagliptin. In a cardiovascular and renal safety study<br />(CARMELINA) with median observation period of 2.2 years, adjudicated acute pancreatitis was reported&nbsp;in 0.3% of patients treated with linagliptin and in 0.1% of patients treated with placebo. Patients should<br />be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, Linagliptin<br />should be discontinued; if acute pancreatitis is confirmed, linagliptin should not be restarted. Caution<br />should be exercised in patients with a history of pancreatitis.<br />Bullous pemphigoid<br />Bullous pemphigoid has been observed in patients taking linagliptin. In the CARMELINA study, bullous<br />pemphigoid was reported in 0.2% of patients on treatment with linagliptin and in no patient on placebo. If<br />bullous pemphigoid is suspected, linagliptin should be discontinued.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In vitro assessment of interactions<br />Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme<br />CYP3A4, but does not inhibit other CYP isozymes. It is not an inducer of CYP isozymes.<br />Linagliptin is a P-glycoprotein substrate, and inhibits P-glycoprotein mediated transport of digoxin with<br />low potency. Based on these results and in vivo interaction studies, linagliptin is considered unlikely to<br />cause interactions with other P-gp substrates.<br />In vivo assessment of interactions<br />Effects of other medicinal products on linagliptin<br />Clinical data described below suggest that the risk for clinically meaningful interactions by coadministered<br />medicinal products is low.<br />Rifampicin: multiple co-administration of 5 mg linagliptin with rifampicin, a potent inductor of Pglycoprotein<br />and CYP3A4, resulted in a 39.6% and 43.8% decreased linagliptin steady-state AUC and<br />Cmax, respectively, and about 30% decreased DPP-4 inhibition at trough. Thus, full efficacy of linagliptin<br />in combination with strong P-gp inducers might not be achieved, particularly if these are administered<br />long-term. Co-administration with other potent inducers of P-glycoprotein and CYP3A4, such as<br />carbamazepine, phenobarbital and phenytoin has not been studied.<br />Ritonavir: co-administration of a single 5 mg oral dose of linagliptin and multiple 200 mg oral doses of<br />ritonavir, a potent inhibitor of P-glycoprotein and CYP3A4, increased the AUC and Cmax of linagliptin<br />approximately twofold and threefold, respectively. The unbound concentrations, which are usually less<br />than 1% at the therapeutic dose of linagliptin, were increased 4-5-fold after co-administration with<br />ritonavir. Simulations of steady-state plasma concentrations of linagliptin with and without ritonavir<br />indicated that the increase in exposure will be not associated with an increased accumulation. These<br />changes in linagliptin pharmacokinetics were not considered to be clinically relevant. Therefore,<br />clinically relevant interactions would not be expected with other P-glycoprotein/CYP3A4 inhibitors.<br />Metformin: co-administration of multiple three times daily doses of 850 mg metformin with 10 mg<br />linagliptin once daily did not clinical meaningfully alter the pharmacokinetics of linagliptin in healthy<br />volunteers.</p><p>Sulphonylureas: the steady-state pharmacokinetics of 5 mg linagliptin was not changed by concomitant<br />administration of a single 1.75 mg dose glibenclamide (glyburide).<br />Effects of linagliptin on other medicinal products<br />In clinical studies, as described below, linagliptin had no clinically relevant effect on the<br />pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin or oral contraceptives<br />providing in vivo evidence of a low propensity for causing medicinal product interactions with substrates<br />of CYP3A4, CYP2C9, CYP2C8, P-glycoprotein, and organic cationic transporter (OCT).<br />Metformin: co-administration of multiple daily doses of 10 mg linagliptin with 850 mg metformin, an<br />OCT substrate, had no relevant effect on the pharmacokinetics of metformin in healthy volunteers.<br />Therefore, linagliptin is not an inhibitor of OCT-mediated transport.<br />Sulphonylureas: co-administration of multiple oral doses of 5 mg linagliptin and a single oral dose of<br />1.75 mg glibenclamide (glyburide) resulted in clinically not relevant reduction of 14% of both AUC and<br />Cmax of glibenclamide. Because glibenclamide is primarily metabolised by CYP2C9, these data also<br />support the conclusion that linagliptin is not a CYP2C9 inhibitor. Clinically meaningful interactions<br />would not be expected with other sulphonylureas (e.g., glipizide, tolbutamide, and glimepiride) which,<br />like glibenclamide, are primarily eliminated by CYP2C9.<br />Digoxin: co-administration of multiple daily doses of 5 mg linagliptin with multiple doses of 0.25 mg<br />digoxin had no effect on the pharmacokinetics of digoxin in healthy volunteers. Therefore, linagliptin is<br />not an inhibitor of P-glycoprotein-mediated transport in vivo.<br />Warfarin: multiple daily doses of 5 mg linagliptin did not alter the pharmacokinetics of S(-) or R(+)<br />warfarin, a CYP2C9 substrate, administered in a single dose.<br />Simvastatin: multiple daily doses of linagliptin had a minimal effect on the steady-state pharmacokinetics<br />of simvastatin, a sensitive CYP3A4 substrate, in healthy volunteers. Following administration of a<br />supratherapeutic dose of 10 mg linagliptin concomitantly with 40 mg of simvastatin daily for 6 days, the<br />plasma AUC of simvastatin was increased by 34%, and the plasma Cmax by 10%.<br />Oral contraceptives: co-administration with 5 mg linagliptin did not alter the steady-state<br />pharmacokinetics of levonorgestrel or ethinylestradiol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The use of linagliptin has not been studied in pregnant women. Animal studies do not indicate direct or<br />indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary<br />measure, it is preferable to avoid the use of linagliptin during pregnancy.<br />Breast-feeding<br />Available pharmacokinetic data in animals have shown excretion of linagliptin/metabolites in milk. A<br />risk to the breast-fed child cannot be excluded. A decision must be made whether to discontinue breastfeeding<br />or to discontinue/abstain from linagliptin therapy taking into account the benefit of breast-feeding<br />for the child and the benefit of therapy for the woman.</p><p>Fertility<br />No studies on the effect on human fertility have been conducted for linagliptin. Animal studies do not<br />indicate direct or indirect harmful effects with respect to fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Linagliptin has no or negligible influence on the ability to drive and use machines. However patients<br />should be alerted to the risk of hypoglycaemia especially when combined with sulphonylurea and/or<br />insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Summary of the safety profile<br />In the pooled analysis of the placebo-controlled trials, the overall incidence of adverse events in patients<br />treated with placebo was similar to linagliptin 5 mg (63.4% versus 59.1%). Discontinuation of therapy<br />due to adverse events was higher in patients who received placebo as compared to linagliptin 5 mg (4.3%<br />versus 3.4%).<br />The most frequently reported adverse reaction was &ldquo;hypoglycaemia&rdquo; observed under the triple<br />combination, linagliptin plus metformin plus sulphonylurea 14.8% versus 7.6% in placebo.<br />In the placebo-controlled studies 4.9% of patients experienced &ldquo;hypoglycaemia&rdquo; as an adverse reaction<br />under linagliptin. Of these, 4.0% were mild and 0.9% were moderate and 0.1% were classified as severe<br />in intensity. Pancreatitis was reported more often in patients randomized to linagliptin (7 events in 6,580<br />patients receiving linagliptin versus 2 events in 4,383 patients receiving placebo).<br />Tabulated list of adverse reactions<br />Due to the impact of the background therapy on adverse reactions (e.g. on hypoglycaemias), adverse<br />reactions were analysed based on the respective treatment regimens (monotherapy, add-on to metformin,<br />add-on to metformin plus sulphonylurea, and add-on to insulin).<br />The placebo-controlled studies included studies where linagliptin was given as<br />- monotherapy with short-term duration of up to 4 weeks<br />- monotherapy with &ge; 12 week duration<br />- add-on to metformin<br />- add-on to metformin + sulphonylurea<br />- add on to metformin and empagliflozin<br />- add-on to insulin with or without metformin</p><p>Adverse reactions classified by system organ class and MedDRA preferred terms reported in patients<br />who received 5 mg linagliptin in double-blind studies as monotherapy or as add-on therapy are presented<br />in the table below (see table 1).<br />The adverse reactions are listed by absolute frequency. Frequencies are defined as very common (&ge; 1/10),<br />common (&ge; 1/100 to &lt;1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare<br />(&lt;1/10,000) or not known (cannot be estimated from the available data).</p><p>Table 1 Adverse reactions reported in patients who received linagliptin 5 mg daily as monotherapy or as add-on therapies in clinical trial and from post-marketing experience</p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="" style="vertical-align:middle"><p><strong>System organ class</strong></p><p>Adverse reaction</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p><strong>Frequency of adverse reaction</strong></p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p><strong>Infections and infestations</strong></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Nasopharyngitis</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>uncommon</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p><strong>Immune system disorders</strong></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Hypersensitivity</p><p>(e.g. bronchial hyperreactivity)</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>uncommon</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p><strong>Metabolism and nutrition disorders</strong></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Hypoglycaemia<sup>1</sup></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>very common</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Cough</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>uncommon</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p><strong>Gastrointestinal disorders</strong></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Pancreatitis</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>rare<sup>#</sup></p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Constipation<sup>2</sup></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>uncommon</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Angioedema*</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>rare</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Urticaria*</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>rare</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Rash*</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>uncommon</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Bullous pemphigoid</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>rare<sup>#</sup></p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p><strong>Investigations</strong></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Amylase increased</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>uncommon</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>Lipase increased**</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>common</p></td></tr></tbody></table><p>* Based on post-marketing experience</p><p>** Based on lipase elevations &gt; 3 &times; ULN observed in clinical trials</p><p><sup>#</sup>&nbsp;Based on&nbsp;<em>Linagliptin cardiovascular and renal safety study (CARMELINA)</em>, see also below</p><p><sup>1</sup>&nbsp;Adverse reaction observed in combination with metformin plus sulphonylurea</p><p><sup>2</sup>&nbsp;Adverse reaction observed in combination with insulin</p><p>Linagliptin cardiovascular and renal safety study (CARMELINA)<br />The CARMELINA study evaluated the cardiovascular and renal safety of linagliptin versus placebo in<br />patients with type 2 diabetes and with increased CV risk evidenced by a history of established<br />macrovascular or renal disease (see section 5.1). The study included 3494 patients treated with linagliptin<br />(5 mg) and 3485 patients treated with placebo. Both treatments were added to standard of care targeting<br />regional standards for HbA1c and CV risk factors. The overall incidence of adverse events and serious<br />adverse events in patients receiving linagliptin was similar to that in patients receiving placebo. Safety<br />data from this study was in line with previous known safety profile of linagliptin.<br />In the treated population, severe hypoglycaemic events (requiring assistance) were reported in 3.0% of<br />patients on linagliptin and in 3.1% on placebo. Among patients who were using sulfonylurea at baseline,<br />the incidence of severe hypoglycaemia was 2.0% in linagliptin-treated patients and 1.7% in placebo<br />treated patients. Among patients who were using insulin at baseline, the incidence of severe<br />hypoglycaemia was 4.4% in linagliptin-treated patients and 4.9% in placebo treated patients.<br />In the overall study observation period adjudicated acute pancreatitis was reported in 0.3% of patients<br />treated with linagliptin and in 0.1% of patients treated with placebo.<br />In the CARMELINA study, bullous pemphigoid was reported in 0.2% of patients treated with linagliptin<br />and in no patient treated with placebo.<br />Reporting of suspected adverse reactions<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />During controlled clinical trials in healthy subjects, single doses of up to 600 mg linagliptin (equivalent<br />to 120 times the recommended dose) were generally well tolerated. There is no experience with doses<br />above 600 mg in humans.<br />Therapy<br />In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., remove<br />unabsorbed material from the gastrointestinal tract, employ clinical monitoring and institute clinical<br />measures if required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors.<br />ATC code: A10BH05<br />Mechanism of action<br />Linagliptin is an inhibitor of the enzyme DPP-4 (dipeptidyl peptidase 4, EC 3.4.14.5) an enzyme which is<br />involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide1, glucosedependent<br />insulinotropic polypeptide). These hormones are rapidly degraded by the enzyme DPP-4. Both<br />incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretins are<br />secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and<br />GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and<br />elevated blood glucose levels. Furthermore GLP-1 also reduces glucagon secretion from pancreatic alpha<br />cells, resulting in a reduction in hepatic glucose output. Linagliptin binds very effectively to DPP-4 in a<br />reversible manner and thus leads to a sustained increase and a prolongation of active incretin levels.<br />Linagliptin glucose-dependently increases insulin secretion and lowers glucagon secretion thus resulting<br />in an overall improvement in the glucose homeostasis. Linagliptin binds selectively to DPP-4 and<br />exhibits a &gt; 10,000 fold selectivity versus DPP-8 or DPP-9 activity in vitro.<br />Clinical efficacy and safety<br />8 phase III randomised controlled trials involving 5,239 patients with type 2 diabetes, of which 3,319<br />were treated with linagliptin were conducted to evaluate efficacy and safety. These studies had 929<br />patients of 65 years and over who were on linagliptin. There were also 1,238 patients with mild renal<br />impairment, and 143 patients with moderate renal impairment on linagliptin. Linagliptin once daily<br />produced clinically significant improvements in glycaemic control, with no clinically relevant change in<br />body weight. The reductions in glycosylated haemoglobin A1c (HbA1c) were similar across different<br />subgroups including gender, age, renal impairment and body mass index (BMI). Higher baseline<br />HbA1c was associated with a greater reduction in HbA1c. There was a significant difference in reduction<br />in HbA1c between Asian patients (0.8%) and White patients (0.5%) in the pooled studies.<br />Linagliptin as monotherapy in patients ineligible for metformin<br />The efficacy and safety of linagliptin monotherapy was evaluated in a double-blind placebo-controlled<br />study of 24 weeks duration. Treatment with once daily linagliptin at 5 mg provided a significant<br />improvement in HbA1c (-0.69% change compared to placebo), in patients with baseline HbA1c of<br />approximately 8%. Linagliptin also showed significant improvements in fasting plasma glucose (FPG),<br />and 2-hour post-prandial glucose (PPG) compared to placebo. The observed incidence of hypoglycaemia<br />in patients treated with linagliptin was similar to placebo.<br />The efficacy and safety of linagliptin monotherapy was also evaluated in patients for whom metformin<br />therapy is inappropriate, due to intolerability or contraindicated due to renal impairment, in a doubleblind<br />placebo-controlled study of 18 weeks duration. Linagliptin provided significant improvements in<br />HbA1c, (-0.57% change compared to placebo), from a mean baseline HbA1c of 8.09%. Linagliptin also<br />showed significant improvements in fasting plasma glucose (FPG) compared to placebo. The observed<br />incidence of hypoglycaemia in patients treated with linagliptin was similar to placebo.</p><p>Linagliptin as add-on to metformin therapy<br />The efficacy and safety of linagliptin in combination with metformin was evaluated in a double-blind<br />placebo-controlled study of 24 weeks duration. Linagliptin provided significant improvements in HbA1c,<br />(-0.64% change compared to placebo), from a mean baseline HbA1c of 8%. Linagliptin also showed<br />significant improvements in fasting plasma glucose (FPG), and 2-hour post-prandial glucose (PPG)<br />compared to placebo. The observed incidence of hypoglycaemia in patients treated with linagliptin was<br />similar to placebo.<br />Linagliptin as add-on to a combination of metformin and sulphonylurea therapy<br />A placebo-controlled study of 24 weeks in duration was conducted to evaluate the efficacy and safety of<br />linagliptin 5 mg to placebo, in patients not sufficiently treated with a combination with metformin and a<br />sulphonylurea. Linagliptin provided significant improvements in HbA1c (-0.62% change compared to<br />placebo), from a mean baseline HbA1c of 8.14%. Linagliptin also showed significant improvements in<br />patients fasting plasma glucose (FPG), and 2-hour post-prandial glucose (PPG), compared to placebo.<br />Linagliptin as add-on to a combination of metformin and empagliflozin therapy<br />In patients inadequately controlled with metformin and empagliflozin (10 mg (n=247) or 25 mg (n=217)),<br />24-weeks treatment with add-on therapy of linagliptin 5 mg provided adjusted mean HbA1c reductions<br />from baseline by -0.53% (significant difference to add-on placebo -0.32% (95% CI -0.52, -0.13) and -<br />0.58% (significant difference to add-on placebo -0.47% (95% CI -0.66; -0.28), respectively. A<br />statistically significant greater proportion of patients with a baseline HbA1c &ge;7.0% and treated with<br />linagliptin 5 mg achieved a target HbA1c of &lt;7% compared to placebo.<br />Linagliptin as add-on to insulin therapy<br />The efficacy and safety of the addition of linagliptin 5 mg to insulin alone or in combination with<br />metformin and/or pioglitazone has been evaluated in a double-blind placebo-controlled study of 24 weeks<br />duration. Linagliptin provided significant improvements in HbA1c (-0.65% compared to placebo) from a<br />mean baseline HbA1c of 8.3%. Linagliptin also provided significant improvements in fasting plasma<br />glucose (FPG), and a greater proportion of patients achieved a target HbA1c of &lt; 7.0%, compared to<br />placebo. This was achieved with a stable insulin dose (40.1 IU). Body weight did not differ significantly<br />between the groups. Effects on plasma lipids were negligible. The observed incidence of hypoglycaemia<br />in patients treated with linagliptin was similar to placebo (22.2% linagliptin; 21.2% placebo).<br />Linagliptin 24 month data, as add-on to metformin in comparison with glimepiride<br />In a study comparing the efficacy and safety of the addition of linagliptin 5 mg or glimepiride (mean dose<br />3 mg) in patients with inadequate glycaemic control on metformin monotherapy, mean reductions in<br />HbA1c were -0.16% with linagliptin (mean baseline HbA1c 7.69%) and -0.36% with glimepiride (mean<br />baseline HbA1c 7.69%.) with a mean treatment difference of 0.20% (97.5% CI: 0.09, 0.299). The<br />incidence of hypoglycaemia in the linagliptin group (7.5%) was significantly lower than that in the<br />glimepiride group (36.1%). Patients treated with linagliptin exhibited a significant mean decrease from<br />baseline in body weight compared to a significant weight gain in patients administered glimepiride (-1.39<br />vs +1.29 kg).<br />Linagliptin as add-on therapy in patients with severe renal impairment, 12 week placebo-controlled data<br />(stable background) and 40 week placebo-controlled extension (adjustable background)</p><p>The efficacy and safety of linagliptin was also evaluated in type 2 diabetes patients with severe renal<br />impairment in a double-blind study versus placebo for 12 weeks duration, during which background<br />glycaemic therapies were kept stable. Most patients (80.5%) received insulin as background therapy,<br />alone or in combination with other oral anti-diabetics such as sulphonylurea, glinide and pioglitazone.<br />There was a further follow up 40 week treatment period during which dose adjustments in antidiabetes<br />background therapies were allowed.<br />Linagliptin provided significant improvements in HbA1c (-0.59 % change compared to placebo after 12<br />weeks), from a mean baseline HbA1c of 8.2%. The observed difference in HbA1c over placebo was -<br />0.72% after 52 weeks.<br />Body weight did not differ significantly between the groups. The observed incidence of hypoglycaemia<br />in patients treated with linagliptin was higher than placebo, due to an increase in asymptomatic<br />hypoglycaemic events. There was no difference between groups in severe hypoglycaemic events.<br />Linagliptin as add-on therapy in elderly (age &ge; 70 years) with type 2 diabetes<br />The efficacy and safety of linagliptin in elderly (age &ge; 70years) with type 2 diabetes was evaluated in a<br />double-blind study of 24 weeks duration. Patients received metformin and/or sulphonylurea and/or<br />insulin as background therapy. Doses of background antidiabetic medicinal products were kept stable<br />during the first 12 weeks, after which adjustments were permitted. Linagliptin provided significant<br />improvements in HbA1c (-0.64 % change compared to placebo after 24 weeks), from a mean baseline<br />HbA1c of 7.8%. Linagliptin also showed significant improvements in fasting plasma glucose (FPG)<br />compared to placebo. Body weight did not differ significantly between the groups.<br />Linagliptin cardiovascular and renal safety study (CARMELINA)<br />CARMELINA was a randomized study in 6979 patients with type 2 diabetes with increased CV risk<br />evidenced by a history of established macrovascular or renal disease who were treated with linagliptin 5<br />mg (3494) or placebo (3485) added to standard of care targeting regional standards for HbA1c, CV risk<br />factors and renal disease. The study population included 1211 (17.4%) patients &ge; 75 years of age and<br />4348 (62.3%) patients with renal impairment. Approximately 19% of the population had eGFR &ge;45 to<br />&lt;60 mL/min/1.73 m2, 28% of the population had eGFR &ge;30 to &lt;45 mL/min/1.73 m2 and 15% had eGFR<br />&lt; 30 mL/min/1.73 m2. The mean HbA1c at baseline was 8.0%.<br />The study was designed to demonstrate non-inferiority for the primary cardiovascular endpoint which<br />was a composite of the first occurrence of cardiovascular death or a non-fatal myocardial infarction (MI)<br />or a non-fatal stroke (3P-MACE). The renal composite endpoint was defined as renal death or sustained<br />end stage renal disease or sustained decrease of 40% or more in eGFR.<br />After a median follow up of 2.2 years, linagliptin, when added to usual care, did not increase the risk of<br />major adverse cardiovascular events or renal outcome events. There was no increased risk in<br />hospitalization for heart failure which was an additional adjudicated endpoint observed compared to<br />usual care without linagliptin in patients with type 2 diabetes (see table 2).<br />Table 2 Cardiovascular and renal outcomes by treatment group in the CARMELINA study</p><p>Table 2 Cardiovascular and renal outcomes by treatment group in the CARMELINA study</p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="2"><p>&nbsp;</p></td><td colspan="2" rowspan=""><p><strong>Linagliptin 5 mg</strong></p></td><td colspan="2" rowspan=""><p><strong>Placebo</strong></p></td><td colspan="" rowspan=""><p><strong>Hazard Ratio</strong></p></td></tr><tr><td colspan="" rowspan=""><p>Number of Subjects (%)</p></td><td colspan="" rowspan=""><p>Incidence Rate per 1 000 PY*</p></td><td colspan="" rowspan=""><p>Number of Subjects (%)</p></td><td colspan="" rowspan=""><p>Incidence Rate per 1 000 PY*</p></td><td colspan="" rowspan=""><p>(95% CI)</p></td></tr><tr><td colspan="" rowspan=""><p>Number of patients</p></td><td colspan="" rowspan=""><p>3 494</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>3 485</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Primary CV composite (Cardiovascular death, non-fatal MI, non-fatal stroke)</p></td><td colspan="" rowspan=""><p>434 (12.4)</p></td><td colspan="" rowspan=""><p>57.7</p></td><td colspan="" rowspan=""><p>420 (12.1)</p></td><td colspan="" rowspan=""><p>56.3</p></td><td colspan="" rowspan=""><p>1.02 (0.89, 1.17)**</p></td></tr><tr><td colspan="" rowspan=""><p>Secondary renal composite (renal death, ESRD, 40% sustained decrease in eGFR)</p></td><td colspan="" rowspan=""><p>327 (9.4)</p></td><td colspan="" rowspan=""><p>48.9</p></td><td colspan="" rowspan=""><p>306 (8.8)</p></td><td colspan="" rowspan=""><p>46.6</p></td><td colspan="" rowspan=""><p>1.04 (0.89, 1.22)</p></td></tr><tr><td colspan="" rowspan=""><p>All-cause mortality</p></td><td colspan="" rowspan=""><p>367 (10.5)</p></td><td colspan="" rowspan=""><p>46.9</p></td><td colspan="" rowspan=""><p>373 (10.7)</p></td><td colspan="" rowspan=""><p>48.0</p></td><td colspan="" rowspan=""><p>0.98 (0.84, 1.13)</p></td></tr><tr><td colspan="" rowspan=""><p>CV death</p></td><td colspan="" rowspan=""><p>255 (7.3)</p></td><td colspan="" rowspan=""><p>32.6</p></td><td colspan="" rowspan=""><p>264 (7.6)</p></td><td colspan="" rowspan=""><p>34</p></td><td colspan="" rowspan=""><p>0.96 (0.81, 1.14)</p></td></tr><tr><td colspan="" rowspan=""><p>Hospitalization for heart failure</p></td><td colspan="" rowspan=""><p>209 (6.0)</p></td><td colspan="" rowspan=""><p>27.7</p></td><td colspan="" rowspan=""><p>226 (6.5)</p></td><td colspan="" rowspan=""><p>30.4</p></td><td colspan="" rowspan=""><p>0.90 (0.74, 1.08)</p></td></tr></tbody></table><p>* PY = patient years</p><p>** Test on non-inferiority to demonstrate that the upper bound of the 95% CI for the hazard ratio is less than 1.3</p><p>In analyses for albuminuria progression (change from normoalbuminuria to micro- or macroalbuminuria, or from microalbuminuria to macroalbuminuria) the estimated hazard ratio was 0.86 (95% CI 0.78, 0.95) for linagliptin versus placebo.</p><p>Linagliptin cardiovascular safety study (CAROLINA)<br />CAROLINA was a randomized study in 6033 patients with early type 2 diabetes and increased CV risk<br />or established complications who were treated with linagliptin 5 mg (3023) or glimepiride 1-4mg (3010)<br />added to standard of care (including background therapy with metformin in 83% of patients) targeting<br />regional standards for HbA1c and CV risk factors. The mean age for study population was 64 years and<br />included 2030 (34%) patients &ge; 70 years of age. The study population included 2089 (35%) patients with<br />cardiovascular disease and 1130 (19%) patients with renal impairment with an eGFR &lt;<br />60ml/min/1.73m2 at baseline. The mean HbA1c at baseline was 7.15%.<br />The study was designed to demonstrate non-inferiority for the primary cardiovascular endpoint which<br />was a composite of the first occurrence of cardiovascular death or a non-fatal myocardial infarction (MI)<br />or a non-fatal stroke (3P-MACE).</p><p>After a median follow up of 6.25 years, linagliptin did not increase the risk of major adverse<br />cardiovascular events (see table 3) as compared to glimepiride. Results were consistent for patients<br />treated with or without metformin.</p><p>Table 3 Major adverse cardiovascular events (MACE) and mortality by treatment group in the CAROLINA study</p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="2"><p>&nbsp;</p></td><td colspan="2" rowspan=""><p><strong>Linagliptin 5 mg</strong></p></td><td colspan="2" rowspan=""><p><strong>Glimepiride (1-4 mg)</strong></p></td><td colspan="" rowspan=""><p><strong>Hazard Ratio</strong></p></td></tr><tr><td colspan="" rowspan=""><p>Number of Subjects (%)</p></td><td colspan="" rowspan=""><p>Incidence Rate per 1 000 PY*</p></td><td colspan="" rowspan=""><p>Number of Subjects (%)</p></td><td colspan="" rowspan=""><p>Incidence Rate per 1 000 PY*</p></td><td colspan="" rowspan=""><p>(95% CI)</p></td></tr><tr><td colspan="" rowspan=""><p>Number of patients</p></td><td colspan="2" rowspan=""><p>3 023</p></td><td colspan="2" rowspan=""><p>3 010</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Primary CV composite (Cardiovascular death, non-fatal MI, non-fatal stroke)</p></td><td colspan="" rowspan=""><p>356 (11.8)</p></td><td colspan="" rowspan=""><p>20.7</p></td><td colspan="" rowspan=""><p>362 (12.0)</p></td><td colspan="" rowspan=""><p>21.2</p></td><td colspan="" rowspan=""><p>0.98 (0.84, 1.14)**</p></td></tr><tr><td colspan="" rowspan=""><p>All-cause mortality</p></td><td colspan="" rowspan=""><p>308 (10.2)</p></td><td colspan="" rowspan=""><p>16.8</p></td><td colspan="" rowspan=""><p>336 (11.2)</p></td><td colspan="" rowspan=""><p>18.4</p></td><td colspan="" rowspan=""><p>0.91 (0.78, 1.06)</p></td></tr><tr><td colspan="" rowspan=""><p>CV death</p></td><td colspan="" rowspan=""><p>169 (5.6)</p></td><td colspan="" rowspan=""><p>9.2</p></td><td colspan="" rowspan=""><p>168 (5.6)</p></td><td colspan="" rowspan=""><p>9.2</p></td><td colspan="" rowspan=""><p>1.00 (0.81, 1.24)</p></td></tr><tr><td colspan="" rowspan=""><p>Hospitalization for heart failure (HHF)</p></td><td colspan="" rowspan=""><p>112 (3.7)</p></td><td colspan="" rowspan=""><p>6.4</p></td><td colspan="" rowspan=""><p>92 (3.1)</p></td><td colspan="" rowspan=""><p>5.3</p></td><td colspan="" rowspan=""><p>1.21 (0.92, 1.59)</p></td></tr></tbody></table><p>* PY = patient years</p><p>** Test on non-inferiority to demonstrate that the upper bound of the 95% CI for the hazard ratio is less than 1.3</p><p>For the entire treatment period (median time on treatment 5.9 years) the rate of patients with moderate or severe hypoglycaemia was 6.5% on linagliptin versus 30.9% on glimepiride, severe hypoglycaemia occurred in 0.3% of patients on linagliptin versus 2.2% on glimepiride.</p><p><em>Paediatric population</em></p><p>The clinical efficacy and safety of empagliflozin 10 mg with potential dose-increase to 25 mg or linagliptin 5 mg once daily has been studied in children and adolescents from 10 to 17 years of age with T2DM in a double-blind, randomised, placebo-controlled, parallel group study (DINAMO) over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks.</p><p>At baseline, the mean HbA1c was 8.03%. Treatment with linagliptin 5 mg did not provide significant improvement in HbA1c. The treatment difference of adjusted mean change in HbA1c after 26 weeks between linagliptin and placebo was -0.34% (95% CI -0.99, 0.30; p = 0.2935). The adjusted mean change in HbA1c from baseline was 0.33% in patients treated with linagliptin and 0.68% in patients treated with placebo (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of linagliptin has been extensively characterised in healthy subjects and patients<br />with type 2 diabetes. After oral administration of a 5 mg dose to healthy volunteers or patients, linagliptin<br />was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1.5 hours post-dose.<br />Plasma concentrations of linagliptin decline in a triphasic manner with a long terminal half-life (terminal<br />half-life for linagliptin more than 100 hours), that is mostly related to the saturable, tight binding of<br />linagliptin to DPP-4 and does not contribute to the accumulation of the medicinal product. The effective<br />half-life for accumulation of linagliptin, as determined from oral administration of multiple doses of 5 mg<br />linagliptin, is approximately 12 hours. After once daily dosing of 5 mg linagliptin, steady-state plasma&nbsp;concentrations are reached by the third dose. Plasma AUC of linagliptin increased approximately 33%<br />following 5 mg doses at steady-state compared to the first dose. The intra-subject and inter-subject<br />coefficients of variation for linagliptin AUC were small (12.6% and 28.5%, respectively). Due to the<br />concentration dependent binding of linagliptin to DPP-4, the pharmacokinetics of linagliptin based on<br />total exposure is not linear; indeed total plasma AUC of linagliptin increased in a less than doseproportional<br />manner while unbound AUC increases in a roughly dose-proportional manner. The<br />pharmacokinetics of linagliptin was generally similar in healthy subjects and in patients with type 2<br />diabetes.<br />Absorption<br />The absolute bioavailability of linagliptin is approximately 30%. Co-administration of a high-fat meal<br />with linagliptin prolonged the time to reach Cmax by 2 hours and lowered Cmax by 15% but no influence<br />on AUC 0-72h was observed. No clinically relevant effect of Cmax and Tmax changes is expected; therefore<br />linagliptin may be administered with or without food.<br />Distribution<br />As a result of tissue binding, the mean apparent volume of distribution at steady-state following a single<br />5 mg intravenous dose of linagliptin to healthy subjects is approximately 1,110 litres, indicating that<br />linagliptin extensively distributes to the tissues. Plasma protein binding of linagliptin is concentrationdependent,<br />decreasing from about 99% at 1 nmol/l to 75-89% at &ge;30 nmol/l, reflecting saturation of<br />binding to DPP-4 with increasing concentration of linagliptin. At high concentrations, where DPP-4 is<br />fully saturated, 70-80% of linagliptin was bound to other plasma proteins than DPP-4, hence 30-20%<br />were unbound in plasma.<br />Biotransformation<br />Following a [14C] linagliptin oral 10 mg dose, approximately 5% of the radioactivity was excreted in<br />urine. Metabolism plays a subordinate role in the elimination of linagliptin. One main metabolite with a<br />relative exposure of 13.3% of linagliptin at steady-state was detected which was found to be<br />pharmacologically inactive and thus does not contribute to the plasma DPP-4 inhibitory activity of<br />linagliptin.<br />Excretion<br />Following administration of an oral [14C] linagliptin dose to healthy subjects, approximately 85% of the<br />administered radioactivity was eliminated in faeces (80%) or urine (5%) within 4 days of dosing. Renal<br />clearance at steady-state was approximately 70 ml/min.<br />Special populations<br />Renal impairment<br />A multiple-dose, open-label study was conducted to evaluate the pharmacokinetics of linagliptin (5 mg<br />dose) in patients with varying degrees of chronic renal insufficiency compared to normal healthy control<br />subjects. The study included patients with renal insufficiency classified on the basis of creatinine<br />clearance as mild (50 to &lt;80 ml/min), moderate (30 to &lt;50 ml/min), and severe (&lt;30 ml/min), as well as<br />patients with ESRD on hemodialysis. In addition patients with T2DM and severe renal impairment (&lt;30&nbsp;ml/min) were compared to T2DM patients with normal renal function. Creatinine clearance was<br />measured by 24-hour urinary creatinine clearance measurements or estimated from serum creatinine<br />based on the Cockcroft-Gault formula. CrCl = (140 &ndash; age) x weight/72 x serum creatinine [x 0.85 for<br />females], where age is in years, weight in kg, and serum creatinine is in mg/dl. Under steady-state<br />conditions, linagliptin exposure in patients with mild renal impairment was comparable to healthy<br />subjects. In moderate renal impairment, a moderate increase in exposure of about 1.7 fold was observed<br />compared with control. Exposure in T2DM patients with severe RI was increased by about 1.4 fold<br />compared to T2DM patients with normal renal function. Steady-state predictions for AUC of linagliptin<br />in patients with ESRD indicated comparable exposure to that of patients with moderate or severe renal<br />impairment. In addition, linagliptin is not expected to be eliminated to a therapeutically significant degree<br />by hemodialysis or peritoneal dialysis. Therefore, no dosage adjustment of linagliptin is necessary in<br />patients with any degree of renal insufficiency.<br />Hepatic impairment<br />In non-diabetic patients with mild moderate and severe hepatic insufficiency (according to the Child-<br />Pugh classification), mean AUC and Cmax of linagliptin were similar to healthy matched controls<br />following administration of multiple 5 mg doses of linagliptin. No dosage adjustment for linagliptin is<br />proposed for diabetic patients with mild, moderate or severe hepatic impairment.<br />Body Mass Index (BMI)<br />No dosage adjustment is necessary based on BMI. BMI had no clinically relevant effect on the<br />pharmacokinetics of linagliptin based on a population pharmacokinetic analysis of Phase I and Phase II<br />data. The clinical trials before marketing authorisation have been performed up to a BMI equal to 40<br />kg/m2.<br />Gender<br />No dosage adjustment is necessary based on gender. Gender had no clinically relevant effect on the<br />pharmacokinetics of linagliptin based on a population pharmacokinetic analysis of Phase I and Phase II<br />data.<br />Elderly<br />No dosage adjustment is required based on age up to 80 years, as age did not have a clinically relevant<br />impact on the pharmacokinetics of linagliptin based on a population pharmacokinetic analysis of Phase I<br />and Phase II data. Older subjects (65 to 80, oldest patient was 78 years) had comparable plasma<br />concentrations of linagliptin compared to younger subjects.<br />Paediatric population<br />A paediatric Phase 2 study examined the pharmacokinetics and pharmacodynamics of 1 mg and 5 mg<br />linagliptin in children and adolescents &ge;10 to &lt;18 years of age with type 2 diabetes mellitus. The<br />observed pharmacokinetic and pharmacodynamic responses were consistent with those found in adult<br />subjects. Linagliptin 5 mg showed superiority over 1 mg with regard to trough DPP-4 inhibition (72% vs<br />32%, p=0.0050) and a numerically larger reduction with regard to adjusted mean change from baseline in<br />HbA1c (-0.63% vs -0.48%, n.s.). Due to the limited nature of the data set the results should be interpreted<br />cautiously.</p><p>Race<br />No dosage adjustment is necessary based on race. Race had no obvious effect on the plasma<br />concentrations of linagliptin based on a composite analysis of available pharmacokinetic data, including<br />patients of Caucasian, Hispanic, African, and Asian origin. In addition the pharmacokinetic<br />characteristics of linagliptin were found to be similar in dedicated phase I studies in Japanese, Chinese<br />and Caucasian healthy volunteers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Liver, kidneys and gastrointestinal tract are the principal target organs of toxicity in mice and rats at<br />repeat doses of linagliptin of more than 300 times the human exposure.<br />In rats effects on reproductive organs, thyroid and the lymphoid organs were seen at more than 1,500<br />times human exposure. Strong pseudo-allergic reactions were observed in dogs at medium doses,<br />secondarily causing cardiovascular changes, which were considered dog-specific. Liver, kidneys,<br />stomach, reproductive organs, thymus, spleen, and lymph nodes were target organs of toxicity in<br />Cynomolgus monkeys at more than 450 times human exposure. At more than 100 times human exposure,<br />irritation of the stomach was the major finding in these monkeys.<br />Linagliptin and its main metabolite did not show a genotoxic potential.<br />Oral 2 year carcinogenicity studies in rats and mice revealed no evidence of carcinogenicity in rats or<br />male mice. A significantly higher incidence of malignant lymphomas only in female mice at the highest<br />dose (&gt; 200 times human exposure) is not considered relevant for humans (explanation: non-treatment<br />related but due to highly variable background incidence). Based on these studies there is no concern for<br />carcinogenicity in humans.<br />The NOAEL for fertility, early embryonic development and teratogenicity in rats was set at &gt;900 times<br />the human exposure. The NOAEL for maternal-, embryo-fetal-, and offspring toxicity in rats was 49<br />times human exposure. No teratogenic effects were observed in rabbits at &gt;1,000 times human exposure.<br />A NOAEL of 78 times human exposure was derived for embryo-fetal toxicity in rabbits, and for maternal<br />toxicity the NOAEL was 2.1 times human exposure. Therefore, it is considered unlikely that linagliptin<br />affects reproduction at therapeutic exposures in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol<br />Pregelatinised Starch-1500<br />Maize Starch<br />Kollidon VA 64 (Copovidone)<br />Magnesium Stearate<br />Opadry white-03B28796<br />Iron Oxide Red<br />Talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg; C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu-Alu Blister.<br />3 blister pack (3 x 10&rsquo;s Tablets)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Factory Company
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov-2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>